Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. (NASDAQ:INVA) with an Overweight rating, citing strong growth prospects from royalties on GSK plc (NYSE:GSK) respiratory drugs. Innoviva's lead pipeline product, zoliflodacin, is on track for an FDA marketing application in early 2025.
June 18, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK plc's respiratory drugs, including Relvar/Breo and Anoro, are generating significant royalties for Innoviva, contributing to strong growth projections.
The strong performance of GSK's respiratory drugs and the resulting royalties for Innoviva are positive indicators for GSK's revenue streams, likely boosting investor confidence.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. with an Overweight rating, highlighting strong growth from royalties on GSK respiratory drugs and a promising pipeline product, zoliflodacin.
The Overweight rating from Cantor Fitzgerald and the strong growth prospects from royalties and pipeline products are likely to positively impact Innoviva's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100